Cocrystal Pharma, Inc. (COCP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on August 5, 2025. The filing serves as a Regulation FD disclosure regarding the presentation of clinical data at the 2025 Military Health System Research Symposium (MHSRS) held in Kissimmee, Florida.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical development updates and does not contain financial statements or performance metrics.
Material Changes
There are no material financial changes reported in this filing. The significant event is the dissemination of safety and tolerability data from a Phase 1 study for the Company's oral, direct-acting pan-viral inhibitor, CDI-988.
Outlook, Commentary, and Risks
- Management Commentary: The Company announced the presentation of data from a randomized, double-blinded, placebo-controlled Phase 1 study for CDI-988.
- Exhibits: The press release (Exhibit 99.1) and the slide presentation (Exhibit 99.2) are furnished with this report.
- Legal Disclaimer: The information in Item 7.01 and its exhibits is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings.
- Risks: No specific risks or contingencies are detailed in the text of this 8-K, though clinical trial outcomes inherently carry development risks.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) and Exhibit 99.2 (Presentation) for specific safety and tolerability data points regarding CDI-988.
- Verify the timeline for subsequent clinical phases or regulatory filings for CDI-988, as this 8-K only covers Phase 1 data presentation.
- Check the Company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K does not contain financial data.